Alterity Therapeutics (ATHE) announced that new presentations related to its Multiple System Atrophy program were delivered at the American ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announc ...

Alterity’s lead candidate, ATH434, is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. ATH434 has been shown preclinically to reduce α ...

ATH434 is a Disease Modifying Drug Candidate Targeting Parkinsonian Disorders –– Topline Data Expected Mid-Year 2025 –MELBOURNE, Australia and ...

The ATH434-202 is an open label study designed to evaluate the safety, efficacy and target engagement of ATH434 in participants with advanced multiple system atrophy (MSA). “Following the ...

David Stamler, M.D., Chief Executive Officer of Alterity, commented,“We are excited to present the positive topline data along with new analyses from our ATH434-201 clinical trial via an oral ...

The ATH434-202 is an open label study designed to evaluate the safety, efficacy and target engagement of ATH434 in participants with advanced multiple system atrophy (MSA). “Following the positive ...

ATH434 is a Disease Modifying Drug Candidate Targeting Parkinsonian Disorders - - Topline Data Expected Mid-Year 2025 - MELBOURNE, Australia and SAN FRANCISCO, March 27, 2025 (GLOBE NEWSWIRE ...